Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Roberts-Thomson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Future Science OA|December 14, 2020
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapyTharani Krishnan, Yoko Tomita, Rachel Roberts-Thomson
Drugs & Aging|April 21, 2020
Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current EvidenceTiffany Foo, Gonzalo Tapia Rico, Rachel Roberts-Thomson
Internal Medicine Journal|March 19, 2021
Recent advancements in melanoma managementTharani Krishnan, Alexander M Menzies, Rachel Roberts-Thomson
Molecular Diagnosis & Therapy|December 16, 2021
Targeting Mutated KRAS Genes to Treat Solid TumoursTharani Krishnan, Rachel Roberts-Thomson, Vy Broadbridge, et al.
JNCI Cancer Spectrum|April 18, 2025
Curative or non-curative: immunotherapy for advanced melanomaRichard Kelly, Abigail Miller, Rachel Roberts-Thomson, et al.
The Australasian Journal of Dermatology|June 6, 2022
Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinomaMichael A Cilento, Oliver Klein, Elizabeth Egan, et al.
Internal Medicine Journal|July 14, 2020
Duration of immunotherapy - should we continue ad infinitum?Annabel Smith, Gohar Shaghayegh, Alexander M Menzies, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 28, 2011
Carboplatin dosing in ovarian cancer: problems and pitfallsIan M Collins, Rachel Roberts-Thomson, David Faulkner, et al.
ANZ Journal of Surgery|July 21, 2021
Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapyB Mark Smithers, Robyn P M Saw, David E Gyorki, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Future Science OA|December 14, 2020
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapyTharani Krishnan, Yoko Tomita, Rachel Roberts-Thomson
Drugs & Aging|April 21, 2020
Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current EvidenceTiffany Foo, Gonzalo Tapia Rico, Rachel Roberts-Thomson
Internal Medicine Journal|March 19, 2021
Recent advancements in melanoma managementTharani Krishnan, Alexander M Menzies, Rachel Roberts-Thomson
Molecular Diagnosis & Therapy|December 16, 2021
Targeting Mutated KRAS Genes to Treat Solid TumoursTharani Krishnan, Rachel Roberts-Thomson, Vy Broadbridge, et al.
JNCI Cancer Spectrum|April 18, 2025
Curative or non-curative: immunotherapy for advanced melanomaRichard Kelly, Abigail Miller, Rachel Roberts-Thomson, et al.
The Australasian Journal of Dermatology|June 6, 2022
Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinomaMichael A Cilento, Oliver Klein, Elizabeth Egan, et al.
Internal Medicine Journal|July 14, 2020
Duration of immunotherapy - should we continue ad infinitum?Annabel Smith, Gohar Shaghayegh, Alexander M Menzies, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 28, 2011
Carboplatin dosing in ovarian cancer: problems and pitfallsIan M Collins, Rachel Roberts-Thomson, David Faulkner, et al.
ANZ Journal of Surgery|July 21, 2021
Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapyB Mark Smithers, Robyn P M Saw, David E Gyorki, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
Pageof 2